TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Manual Physical Therapy Approach Versus Subacromial Corticosteroid Injection for Treatment of Shoulder Impingement Syndrome: a Randomized Clinical Trial
Brief Summary: The purpose of this study is to evaluate and compare the short and long-term effectiveness of two common interventions, manual physical therapy versus corticosteroid injection, for the treatment of shoulder impingement syndrome.


Options:
A: Arm Label: Manual Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Manual Physical Therapy | Arm Label: Corticosteroid Injection (Subacromial); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Corticosteroid Injection | Intervention Type: PROCEDURE; Name: Manual Physical Therapy; Assigned to Arm(s): Manual Physical Therapy | Intervention Type: PROCEDURE; Name: Corticosteroid Injection; Assigned to Arm(s): Corticosteroid Injection (Subacromial)
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Physical therapy method called Supervised Exercises | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radial Extracorporeal Shockwave Therapy | Intervention Type: PROCEDURE; Name: Physical therapy method called Supervised Exercises; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Radial Extracorporeal Shockwave Therapy; Assigned to Arm(s): B
C: Arm Label: Active physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Physiotherapy program | Arm Label: Placebo physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo physiotherapy treatment | Intervention Type: PROCEDURE; Name: Physiotherapy program; Assigned to Arm(s): Active physiotherapy | Intervention Type: PROCEDURE; Name: Placebo physiotherapy treatment; Assigned to Arm(s): Placebo physiotherapy
D: Arm Label: 1: Dynamic humeral centering; Type: EXPERIMENTAL; Interventions: Procedure: Dynamic humeral centering | Arm Label: 2: Nonspecific mobilisation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Nonspecific mobilisation | Intervention Type: PROCEDURE; Name: Dynamic humeral centering; Assigned to Arm(s): 1: Dynamic humeral centering | Intervention Type: PROCEDURE; Name: Nonspecific mobilisation; Assigned to Arm(s): 2: Nonspecific mobilisation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Brief Summary: This is up to a 58 week study comparing ferric citrate to active control for 52 weeks in ESRD dialysis patients, and subsequently comparing ferric citrate to placebo for 4 weeks.


Options:
A: Arm Label: Active Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo | Arm Label: KRX-0502 (Ferric Citrate); Type: EXPERIMENTAL; Interventions: Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo | Intervention Type: DRUG; Name: ferric citrate, ca acetate, sevelamer carbonate, placebo; Assigned to Arm(s): Active Control, KRX-0502 (Ferric Citrate), Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Calcium Carbonate (Phosphate Binder); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 1500 mg/d elemental calcium as calcium carbonate | Intervention Type: DIETARY_SUPPLEMENT; Name: 1500 mg/d elemental calcium as calcium carbonate; Assigned to Arm(s): Calcium Carbonate (Phosphate Binder) | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: SBR759A | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: SBR759A | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: SBR759A | Arm Label: arm 4; Type: EXPERIMENTAL; Interventions: Drug: SBR759A | Arm Label: arm 5; Type: EXPERIMENTAL; Interventions: Drug: SBR759A | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): arm 4 | Intervention Type: DRUG; Name: SBR759A; Assigned to Arm(s): arm 5
D: Arm Label: Chewing Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum | Arm Label: Chewing Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Other: K2CG chewing gum | Arm Label: Chewing Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum | Arm Label: Chewing Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum | Intervention Type: OTHER; Name: K2CG chewing gum; Assigned to Arm(s): Chewing Arm 1, Chewing Arm 2, Chewing Arm 3, Chewing Arm 4 | Intervention Type: OTHER; Name: K2CG chewing gum; Assigned to Arm(s): Chewing Arm 1, Chewing Arm 2, Chewing Arm 3, Chewing Arm 4 | Intervention Type: OTHER; Name: K2CG chewing gum; Assigned to Arm(s): Chewing Arm 1, Chewing Arm 2, Chewing Arm 3, Chewing Arm 4 | Intervention Type: OTHER; Name: K2CG chewing gum; Assigned to Arm(s): Chewing Arm 1, Chewing Arm 2, Chewing Arm 3, Chewing Arm 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Brief Summary: The purpose of this study is to assess the efficacy and safety of LY2189265 in comparison to Insulin Glargine, both in combination with Insulin Lispro (plus or minus Metformin), in participants with Type 2 Diabetes treated with 1 or 2 injections of insulin.


Options:
A: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
B: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Dapagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Dapagliflozin 10 MG | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Dapagliflozin 10 MG; Assigned to Arm(s): Dapagliflozin
C: Arm Label: 1.5 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Insulin Lispro | Arm Label: 0.75 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Insulin Lispro | Arm Label: Insulin Glargine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine, Drug: Insulin Lispro | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): Insulin Glargine | Intervention Type: DRUG; Name: LY2189265; Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265 | Intervention Type: DRUG; Name: Insulin Lispro; Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265, Insulin Glargine
D: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glipizide | Arm Label: glipizide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Glipizide; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): glipizide

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Multinational, Single-Dose, Open Label, Randomized, 2-Way Crossover, Clinical Pharmacology Study of CHF 1535 100/6 Next™ DPI (Fixed Combination of Beclomethasone Dipropionate 100 µg Plus Formoterol 6 µg) Versus the Free Combination of Licensed Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescents and Adult Patients
Brief Summary: The purpose of this study is to demonstrate that the CHF 1535 (fixed combination of Beclometasone Dipropionate (BDP) 100 µg / Formoterol Fumarate (FF) 6 µg) delivered via the NEXT Dry Powder Inhaler (DPI) does not show a greater exposure to BDP, Beclometasone-17-Monopropionate(B17MP, active metabolite of BDP) and FF in comparison to a free combination of BDP DPI plus FF DPI licensed products after a morning dose administration of BDP and FF (total dose of BDP 400 µg / FF 24 µg) in adolescent and adult asthmatic patients.


Options:
A: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID
B: Arm Label: Fixed Combination of Budesonide and formoterol; Type: EXPERIMENTAL; Interventions: Drug: Fixed combination of budesonide and formoterol | Arm Label: Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Intervention Type: DRUG; Name: Fixed combination of budesonide and formoterol; Assigned to Arm(s): Fixed Combination of Budesonide and formoterol | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide
C: Arm Label: CHF1535 NEXT DPI; Type: EXPERIMENTAL; Interventions: Drug: CHF1535 NEXT DPI | Arm Label: Free combination BDP and FF; Type: ACTIVE_COMPARATOR; Interventions: Drug: BDP DPI and formoterol DPI | Intervention Type: DRUG; Name: CHF1535 NEXT DPI; Assigned to Arm(s): CHF1535 NEXT DPI | Intervention Type: DRUG; Name: BDP DPI and formoterol DPI; Assigned to Arm(s): Free combination BDP and FF
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate/Formoterol Fumarate 100/10 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate 100 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol fumarate 10 | Intervention Type: DRUG; Name: Fluticasone propionate/Formoterol Fumarate 100/10; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fluticasone propionate 100; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Formoterol fumarate 10; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Between High-flow Conditioned Oxygen Therapy and Non-invasive Ventilation in Prevention of Post-extubation Respiratory Failure. A Randomized Controlled Trial
Brief Summary: The main aim is to demonstrate whether the high flow conditioned oxygen therapy reduces the reintubation rate. Post-extubation respiratory failure risk will be stratified (as the randomization). In high risk patients high flow conditioned oxygen therapy will be compared with with not conditioned non-invasive mechanical ventilation. In low risk patients comparison will be conventional oxygen therapy. Hypercapnic patients will be excluded.


Options:
A: Arm Label: standard oxygen group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard oxygen | Arm Label: High-flow nasal oxygen (HFNO) group; Type: EXPERIMENTAL; Interventions: Procedure: HFNO | Intervention Type: PROCEDURE; Name: standard oxygen; Assigned to Arm(s): standard oxygen group | Intervention Type: PROCEDURE; Name: HFNO; Assigned to Arm(s): High-flow nasal oxygen (HFNO) group
B: Arm Label: NIV/HFNC group; Type: ACTIVE_COMPARATOR; Interventions: Device: NIV/HFNC | Arm Label: HFNC group; Type: EXPERIMENTAL; Interventions: Device: HFNC | Intervention Type: DEVICE; Name: NIV/HFNC; Assigned to Arm(s): NIV/HFNC group | Intervention Type: DEVICE; Name: HFNC; Assigned to Arm(s): HFNC group
C: Arm Label: High Flow Conditioned Oxygen Therapy in high risk patients; Type: EXPERIMENTAL; Interventions: Device: High Flow Conditioned Oxygen Therapy in High Risk Patients | Arm Label: Non-invasive mechanical ventilation in High Risk Patients; Type: ACTIVE_COMPARATOR; Interventions: Device: Non-invasive mechanical ventilation | Arm Label: High Flow Conditioned Oxygen Therapy in Low Risk Patients; Type: EXPERIMENTAL; Interventions: Device: High Flow Conditioned Oxygen Therapy in High Risk Patients | Arm Label: Conventional Oxygen Therapy in Low Risk Patients; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional Oxygen Therapy | Intervention Type: DEVICE; Name: High Flow Conditioned Oxygen Therapy in High Risk Patients; Assigned to Arm(s): High Flow Conditioned Oxygen Therapy in Low Risk Patients, High Flow Conditioned Oxygen Therapy in high risk patients | Intervention Type: DEVICE; Name: Non-invasive mechanical ventilation; Assigned to Arm(s): Non-invasive mechanical ventilation in High Risk Patients | Intervention Type: DEVICE; Name: Conventional Oxygen Therapy; Assigned to Arm(s): Conventional Oxygen Therapy in Low Risk Patients
D: Arm Label: Venturi mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Venturi mask | Arm Label: Nasal high-flow; Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal high-flow | Intervention Type: DEVICE; Name: Venturi mask; Assigned to Arm(s): Venturi mask | Intervention Type: DEVICE; Name: Nasal high-flow; Assigned to Arm(s): Nasal high-flow

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Adductor-Canal-Blockade on Pain and Morphine Consumption After Revision Knee Arthroplasty
Brief Summary: The purpose of this study is to determine whether Adductor-Canal-Blockade is effective at reducing pain and morphine consumption after revision knee arthroplasty.


Options:
A: Arm Label: Adductor-Canal-Blockade with ropivacaine; Type: EXPERIMENTAL; Interventions: Procedure: Adductor-Canal-Blockade with Ropivacaine | Arm Label: Adductor-Canal-blockade with saline; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Adductor-Canal-blockade with saline | Intervention Type: PROCEDURE; Name: Adductor-Canal-Blockade with Ropivacaine; Assigned to Arm(s): Adductor-Canal-Blockade with ropivacaine | Intervention Type: PROCEDURE; Name: Adductor-Canal-blockade with saline; Assigned to Arm(s): Adductor-Canal-blockade with saline
B: Arm Label: Adductor-Canal-Blockade with Ropivacaine; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Adductor-Canal-Blockade with Ropivacaine | Arm Label: Adductor-Canal-blockade with saline; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Adductor-Canal-blockade with saline | Intervention Type: PROCEDURE; Name: Adductor-Canal-Blockade with Ropivacaine; Assigned to Arm(s): Adductor-Canal-Blockade with Ropivacaine | Intervention Type: PROCEDURE; Name: Adductor-Canal-blockade with saline; Assigned to Arm(s): Adductor-Canal-blockade with saline
C: Arm Label: Adductor-Canal-Blockade; Type: EXPERIMENTAL; Interventions: Procedure: Adductor-Canal-Blockade | Arm Label: The femoral nerve block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: The femoral nerve block | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo | Intervention Type: PROCEDURE; Name: Adductor-Canal-Blockade; Assigned to Arm(s): Adductor-Canal-Blockade | Intervention Type: PROCEDURE; Name: The femoral nerve block; Assigned to Arm(s): The femoral nerve block | Intervention Type: PROCEDURE; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Adductor-Canal-Blockade; Type: EXPERIMENTAL; Interventions: Procedure: Adductor-Canal-Blockade | Arm Label: Femoral Nerve Block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Femoral Nerve Block | Intervention Type: PROCEDURE; Name: Adductor-Canal-Blockade; Assigned to Arm(s): Adductor-Canal-Blockade | Intervention Type: PROCEDURE; Name: Femoral Nerve Block; Assigned to Arm(s): Femoral Nerve Block

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is the Clinical Outcome Affected by the Incidence of Progesterone Elevation on the Day of hCG Triggering When Agonist Protocol is Compared to Antagonist Protocol for IVF
Brief Summary: The aim is to explore whether the incidence of progesterone rise in the late follicular phase differs between GnRH-agonist and GnRH-antagonist protocols for IVF and whether this has an impact on the probability of pregnancy achievement.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Patients receiving short protocol IVF/ICSI-treatment. | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Long protocol | Intervention Type: DRUG; Name: Patients receiving short protocol IVF/ICSI-treatment.; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Long protocol; Assigned to Arm(s): 2
B: Arm Label: Antagonist group; Type: EXPERIMENTAL; Interventions: Other: In vitro fertilization | Arm Label: Agonist group; Type: ACTIVE_COMPARATOR; Interventions: Other: In vitro fertilization | Intervention Type: OTHER; Name: In vitro fertilization; Assigned to Arm(s): Agonist group, Antagonist group
C: Arm Label: Observational Cohort; Type: N/A; Interventions: Drug: ganirelix | Arm Label: Historical Controls; Type: N/A; Interventions: Drug: GnRH agonist | Intervention Type: DRUG; Name: ganirelix; Assigned to Arm(s): Observational Cohort | Intervention Type: DRUG; Name: GnRH agonist; Assigned to Arm(s): Historical Controls
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ganirelix | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: triptorelin | Intervention Type: DRUG; Name: ganirelix; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: triptorelin; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open Label, Parallel-group, Multi-center Trial to Compare the Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery
Brief Summary: The efficacy and safety of TachoSil® as secondary hemostatic treatment in hepatic resection surgery will be compared to the standard USA licensed hemostatic agent, Surgicel® Original. Hemostatic efficacy will be evaluated intraoperatively after application of randomized treatment.


Options:
A: Arm Label: TachoSil®; Type: ACTIVE_COMPARATOR; Interventions: Biological: TachoSil® | Arm Label: Surgicel® Original; Type: ACTIVE_COMPARATOR; Interventions: Device: Surgicel® Original | Intervention Type: BIOLOGICAL; Name: TachoSil®; Assigned to Arm(s): TachoSil® | Intervention Type: DEVICE; Name: Surgicel® Original; Assigned to Arm(s): Surgicel® Original
B: Arm Label: Sangustop; Type: EXPERIMENTAL; Interventions: Device: Sangustop | Arm Label: Tachosil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tachosil | Intervention Type: DEVICE; Name: Sangustop; Assigned to Arm(s): Sangustop | Intervention Type: DRUG; Name: Tachosil; Assigned to Arm(s): Tachosil
C: Arm Label: Fibrocaps + Gelatin Sponge; Type: EXPERIMENTAL; Interventions: Biological: Fibrocaps, Biological: Gelatin sponge | Arm Label: Gelatin Sponge; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gelatin sponge | Intervention Type: BIOLOGICAL; Name: Fibrocaps; Assigned to Arm(s): Fibrocaps + Gelatin Sponge | Intervention Type: BIOLOGICAL; Name: Gelatin sponge; Assigned to Arm(s): Fibrocaps + Gelatin Sponge, Gelatin Sponge
D: Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Drug: No tranexamic acid | Arm Label: Dose 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Dose 2; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Intervention Type: DRUG; Name: No tranexamic acid; Assigned to Arm(s): Standard Care | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Dose 1, Dose 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Beneficial Effects of a Protein-rich Breakfast on Appetite Control & Cognition in Overweight and Obese Adolescents
Brief Summary: The purpose of this study is to assess whether the daily addition of a protein-rich breakfast leads to beneficial changes in appetite control, food intake regulation,and cognitive function in overweight \& obese 'breakfast skipping' young women.


Options:
A: Arm Label: "Fortaleça sua Saúde" program; Type: EXPERIMENTAL; Interventions: Behavioral: "Fortaleça sua Saúde" program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: "Fortaleça sua Saúde" program; Assigned to Arm(s): "Fortaleça sua Saúde" program
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Intervention group
C: Arm Label: Breakfast Skipping; Type: EXPERIMENTAL; Interventions: Behavioral: Breakfast Skipping | Arm Label: Normal Protein Breakfast Meals; Type: EXPERIMENTAL; Interventions: Behavioral: Normal Protein Breakfast Meals | Arm Label: Protein-rich Breakfast Meals; Type: EXPERIMENTAL; Interventions: Behavioral: Protein-rich Breakfast Meals | Intervention Type: BEHAVIORAL; Name: Breakfast Skipping; Assigned to Arm(s): Breakfast Skipping | Intervention Type: BEHAVIORAL; Name: Normal Protein Breakfast Meals; Assigned to Arm(s): Normal Protein Breakfast Meals | Intervention Type: BEHAVIORAL; Name: Protein-rich Breakfast Meals; Assigned to Arm(s): Protein-rich Breakfast Meals
D: Intervention Type: BEHAVIORAL; Name: Switch active lifestyles brought to you by MediaWise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Switch active lifestyles from MediaWise; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Beneficial Effects of a Protein-rich Breakfast on Appetite Control & Cognition in Overweight and Obese Adolescents
Brief Summary: The purpose of this study is to assess whether the daily addition of a protein-rich breakfast leads to beneficial changes in appetite control, food intake regulation,and cognitive function in overweight \& obese 'breakfast skipping' young women.


Options:
A: Arm Label: Breakfast Skipping; Type: EXPERIMENTAL; Interventions: Behavioral: Breakfast Skipping | Arm Label: Normal Protein Breakfast Meals; Type: EXPERIMENTAL; Interventions: Behavioral: Normal Protein Breakfast Meals | Arm Label: Protein-rich Breakfast Meals; Type: EXPERIMENTAL; Interventions: Behavioral: Protein-rich Breakfast Meals | Intervention Type: BEHAVIORAL; Name: Breakfast Skipping; Assigned to Arm(s): Breakfast Skipping | Intervention Type: BEHAVIORAL; Name: Normal Protein Breakfast Meals; Assigned to Arm(s): Normal Protein Breakfast Meals | Intervention Type: BEHAVIORAL; Name: Protein-rich Breakfast Meals; Assigned to Arm(s): Protein-rich Breakfast Meals
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: placebo | Arm Label: lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: multimodal lifestyle intervention | Intervention Type: BEHAVIORAL; Name: multimodal lifestyle intervention; Assigned to Arm(s): lifestyle intervention | Intervention Type: BEHAVIORAL; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Physical activity; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): Physical activity
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: MOVI-KIDS Program; Type: EXPERIMENTAL; Interventions: Behavioral: MOVI-KIDS | Intervention Type: BEHAVIORAL; Name: MOVI-KIDS; Assigned to Arm(s): MOVI-KIDS Program

Answer: A